Connect your AI

Janux Therapeutics JANX Earnings yield

Earnings yield at other companies

Johnson & JohnsonJNJ

3.6%-1.9pp

AmgenAMGN

4.1%+0.6pp

Regeneron PharmaceuticalsREGN

5.4%-1.1pp

XencorXNCR

-19.5%-4.5pp

AbbVieABBV

0.9%-0.2pp

Vor BiopharmaVOR

-733.6%-1,389pp

Other financials

Income statement

Revenue$3.7M—

Operating income-$34.2M+2.0%

Net income-$24.4M-3.6%

EPS (diluted)-$0.39-2.6%

Balance sheet

Cash & equivalents$51.8M-29.7%

Total debt$21.6M-4.6%

Total equity$941.5M-7.0%

Total assets$1.0B-2.1%

Cash flow

Operating cash flow-$12.3M+27.5%

CapEx$273.0K-26.4%

Free cash flow-$12.6M+27.5%

Valuation

Market cap$892.81M-36.3%

Enterprise value$862.55M-36.2%

P/S65×-85.2×

Profitability

Operating margin-1,143.1%-65.1pp

Net margin-833.6%+0.9pp

FCF margin-571.6%+98.3pp

Returns & leverage

Return on equity-11.7%+4.1pp

Debt / equity0×0.0×

Current ratio17×-41.5×

Where this comes from

Calculated from Janux Therapeutics’s reported figures.

net income/market cap=-13.5%

Based on trailing twelve months.

The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Janux Therapeutics's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Janux Therapeutics's earnings yield?: Janux Therapeutics (JANX) reported earnings yield of -13.5% in Q1 2026.
How has Janux Therapeutics's earnings yield changed year-over-year?: Janux Therapeutics's earnings yield decreased by 177.9% year-over-year, from -4.9% to -13.5%.
What is the long-term trend for Janux Therapeutics's earnings yield?: Over 4 years (2021 to 2025), Janux Therapeutics's earnings yield has grown at a 35.9% compound annual growth rate (CAGR), from -4% to -13.7%.
What does earnings yield mean?: Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.